

### Evolve launches nootkatone for F&F

#### US EPA letter facilitates potential approval as tick and insect repellent

**21 August 2015** – Evolve (SIX: EVE) announces the launch of [nootkatone](#), a highly prized citrus flavour and fragrance (F&F) ingredient. By brewing nootkatone from sugar, rather than extracting it from the skin of grapefruits, Evolve's process allows nootkatone to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolve has now begun selling nootkatone as a F&F ingredient to food, beverage, personal care, and home care product producers around the world.

Nootkatone is a natural aroma ingredient that occurs in grapefruit and certain other plants. It is responsible for the characteristic smell of grapefruit. With a record of demonstrated safety, it is approved in all major countries for use in F&F, and is used in a wide range of foods, drinks, and skin care products. However, until now, its use has been limited by its high price, limited supply, product quality, and other factors.

But nootkatone's commercial prospects go significantly beyond F&F. In both laboratory and field studies, nootkatone has demonstrated excellent activity against biting and nuisance pests, notably the ticks that are responsible for spreading Lyme disease, but also mosquitoes, head lice, bed bugs and other pests. Earlier this year Evolve therefore submitted a request to the US Environmental Protection Agency (EPA) to classify nootkatone as a biochemical pesticide active ingredient (a subcategory of biopesticide). Such a classification allows for a potentially expedited process for registration of nootkatone for use against pests. Evolve received approval of this request on 19<sup>th</sup> August, and will now engage in an estimated 2-3 years of regulatory work to get nootkatone approved as an insect and tick repellent in the USA. Evolve is also investigating other geographies.

Nootkatone's revenue and bottom line impact on Evolve will initially be modest and the launch does not affect Evolve's financial projections for 2015. Revenues and net income are expected to increase significantly from 2016 onwards. Until final EPA approval is obtained, all revenues in the USA at least will come from F&F applications.

"Nootkatone is one of Evolve's most exciting products," Evolve CEO **Neil Goldsmith** said. "Since we are committed to improving public health through better functional ingredients, we are doing our part to ensure that nootkatone reaches its full potential—responsibly, but expeditiously."

## About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva's products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see [www.evolva.com](http://www.evolva.com). Questions about our fermentation approach? Have a look at [our video](#).

## About Biopesticides, Ticks, Lyme Disease & Repellents

Information about the EPA classification system for biopesticides can be found [here](#).

Most people develop Lyme disease from the bite of an immature tick, which is tiny (less than 2 mm across), difficult to see, and as a result often goes completely unnoticed. Information about ticks and how to identify them can be [found here](#). Recent information about the spread of Lyme Disease in the USA can be [found here](#). Information from the US Centers for Disease Control and Prevention on tick repellents including nootkatone can be [found here](#).

## Contact Details

Neil Goldsmith, CEO  
[neilg@evolva.com](mailto:neilg@evolva.com)  
+ 41 61 485 2005

Jakob Dynnes Hansen, CFO  
[jakobdh@evolva.com](mailto:jakobdh@evolva.com)  
+ 41 61 485 2034

Paul Verbraeken, IR  
[paulv@evolva.com](mailto:paulv@evolva.com)  
+ 41 61 485 2035

Commercial enquiries  
[noot@evolva.com](mailto:noot@evolva.com)  
North America  
+ 1 800 250 1032  
Rest of world  
+ 41 61 485 2099

*This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.*